{"address1": "2200 N. Commerce Parkway", "address2": "Suite 208", "city": "Weston", "state": "FL", "zip": "33326", "country": "United States", "phone": "754 231 1688", "website": "https://www.zyversa.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Stephen C. Glover", "age": 64, "title": "Co-Founder, Chairman, CEO & President", "yearBorn": 1960, "fiscalYear": 2024, "totalPay": 550000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Peter  Wolfe", "age": 56, "title": "CFO & Secretary", "yearBorn": 1968, "fiscalYear": 2024, "totalPay": 395000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Pablo A. Guzman FACC, M.D.", "age": 74, "title": "Chief Medical Officer, Senior VP of Medical Affairs & Chairman of Renal Scientific Advisory Board", "yearBorn": 1950, "fiscalYear": 2024, "totalPay": 350000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Melda  Uzbil O'connell", "title": "Senior Vice President of Corporate Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Karen A. Cashmere", "age": 72, "title": "Chief Commercial Officer", "yearBorn": 1952, "fiscalYear": 2024, "totalPay": 410000, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.6286, "open": 0.5802, "dayLow": 0.5802, "dayHigh": 0.62, "regularMarketPreviousClose": 0.6286, "regularMarketOpen": 0.5802, "regularMarketDayLow": 0.5802, "regularMarketDayHigh": 0.62, "payoutRatio": 0.0, "forwardPE": -0.12239582, "volume": 26937, "regularMarketVolume": 26937, "averageVolume": 866168, "averageVolume10days": 64270, "averageDailyVolume10Day": 64270, "bid": 0.5497, "ask": 0.6189, "bidSize": 1, "askSize": 1, "marketCap": 1473555, "fiftyTwoWeekLow": 0.58, "fiftyTwoWeekHigh": 8.05, "fiftyDayAverage": 1.07604, "twoHundredDayAverage": 2.11149, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -22110, "profitMargins": 0.0, "floatShares": 2561719, "sharesOutstanding": 2508180, "sharesShort": 187928, "sharesShortPriorMonth": 97759, "sharesShortPreviousMonthDate": 1739491200, "dateShortInterest": 1741910400, "sharesPercentSharesOut": 0.0749, "heldPercentInsiders": 0.00245, "heldPercentInstitutions": 0.031570002, "shortRatio": 0.44, "shortPercentOfFloat": 0.075100005, "impliedSharesOutstanding": 2508180, "bookValue": 3.395, "priceToBook": 0.1730486, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -9413435, "trailingEps": -8.48, "forwardEps": -4.8, "lastSplitFactor": "1:10", "lastSplitDate": 1714089600, "enterpriseToEbitda": 0.002, "52WeekChange": -0.91753155, "SandP52WeekChange": 0.08089435, "quoteType": "EQUITY", "currentPrice": 0.5875, "recommendationKey": "none", "totalCash": 1530924, "totalCashPerShare": 0.596, "ebitda": -9129901, "totalDebt": 0, "quickRatio": 0.136, "currentRatio": 0.153, "returnOnAssets": -0.26739, "returnOnEquity": -0.96099, "freeCashflow": -4796470, "operatingCashflow": -7559697, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "ZVSA", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": -6.5383434, "regularMarketPrice": 0.5875, "marketState": "PRE", "shortName": "ZyVersa Therapeutics, Inc.", "longName": "ZyVersa Therapeutics, Inc.", "fiftyDayAverageChange": -0.48854005, "fiftyDayAverageChangePercent": -0.45401663, "twoHundredDayAverageChange": -1.52399, "twoHundredDayAverageChangePercent": -0.72176045, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1644589800000, "preMarketChange": 0.05550003, "preMarketChangePercent": 9.446815, "preMarketPrice": 0.643, "regularMarketChange": -0.041100025, "regularMarketDayRange": "0.5802 - 0.62", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 866168, "fiftyTwoWeekLowChange": 0.007499993, "fiftyTwoWeekLowChangePercent": 0.012931023, "fiftyTwoWeekRange": "0.58 - 8.05", "fiftyTwoWeekHighChange": -7.4625, "fiftyTwoWeekHighChangePercent": -0.92701864, "fiftyTwoWeekChangePercent": -91.75316, "earningsTimestamp": 1743081300, "earningsTimestampStart": 1747139400, "earningsTimestampEnd": 1747657800, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -8.48, "epsForward": -4.8, "corporateActions": [], "preMarketTime": 1743595202, "regularMarketTime": 1743537600, "exchange": "NCM", "messageBoardId": "finmb_268178409", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "displayName": "ZyVersa Therapeutics", "trailingPegRatio": null}